Hepatitis C Virus Infection As a Risk Factor for Non-alcoholic Liver Cirrhosis in Taiwan
Overview
Affiliations
To assess whether hepatitis C virus infection was a risk factor for the development of non-alcoholic liver cirrhosis, antibody to hepatitis C virus (anti-HCV; detected by a second generation HCV enzyme immunoassay), hepatitis B surface antigen (HBsAg; detected by radioimmunoassay) were tested in 150 cirrhotics and 150 sex-matched and age-matched healthy controls. The prevalence of anti-HCV and HBsAg in cirrhotics was higher than in controls (22.0%, 73.3% vs. 2%, 18.7%; P = 0.001). The prevalence of anti-HCV in HBsAg-negative cirrhotics (45.0%) was higher than that in HBsAg-positive patients (13.6%; P = 0.001). Both the anti-HCV and carriage of HBsAg were associated significantly with liver cirrhosis, showing odds ratio of 12.0 for HBsAg carriers and 13.8 for patients with anti-HCV. Compared with those without HBsAg and anti-HCV, there was a significantly positive linear trend for developing cirrhosis with the presence of HBsAg alone (odds ratio = 19.9), anti-HCV alone (odds ratio = 49.0), and those positive for HBsAg and anti-HCV (odds ratio = 81.8) (P = 0.00001). The population-attributable risk for developing liver cirrhosis was estimated as 10.8% for anti-HCV alone, 55.2% for HBsAg alone, and 9.4% for both anti-HCV and HBsAg in southern Taiwan. In conclusion, this study shows that hepatitis B and C virus infection act independently and synergistically in the development of non-alcoholic liver cirrhosis among Chinese in Taiwan.
Association of type 2 diabetes with liver cirrhosis: a nationwide cohort study.
Hsieh P, Huang J, Nfor O, Lung C, Ho C, Liaw Y Oncotarget. 2017; 8(46):81321-81328.
PMID: 29113391 PMC: 5655286. DOI: 10.18632/oncotarget.18466.
Lin H, Lai S, Lin W, Liu C, Lin C, Chang C Biomedicine (Taipei). 2016; 6(2):11.
PMID: 27161001 PMC: 4864771. DOI: 10.7603/s40681-016-0011-7.
Liver cirrhosis in selected autoimmune diseases: a nationwide cohort study in Taiwan.
Tung C, Lai N, Lu M, Lee C Rheumatol Int. 2015; 36(2):199-205.
PMID: 26408009 DOI: 10.1007/s00296-015-3369-z.
Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma.
Li J, Cheng Z, Liu Y, Yan Z, Wang K, Wu D Oncotarget. 2015; 6(11):9551-63.
PMID: 25871387 PMC: 4496238. DOI: 10.18632/oncotarget.3314.
Hung T, Hsieh M, Lay C, Tsai C, Tsai C Prz Gastroenterol. 2015; 9(6):342-7.
PMID: 25653729 PMC: 4300349. DOI: 10.5114/pg.2014.47896.